DAFTAR PUSTAKA

1. Assmann G, Eckardstein V, Cullen P. Dislipidemias. Dalam Fernandes J,

Saudubray JM, Van de Berghe G (penyunting). Inborn Metabolic Disease
Diagnosis and Treatment.Edisi 2. Springer-Verlag Berlin Heidelberg New
York 1996; 261-285.
2. Boedhi-darmojo R. Bersama MONICA melaksanakan hidup sehat. Bunga
Rampai Karangan Ilmiah Prof. Dr. R Boedhi-Darmojo. Semarang : FK
UNDIP. 1994; 433-50.
3. Brown MS, Goldstein . A Receptor Mediated Pathway for Cholesterol
Homeostasis. Science 1986;232;284-316.
4. Damgaard D, Larsen LM, Nissen PH, Jensen JM, dkk.The relationship of
molekular genetic to clinical diagnosis of familial hypercholesterolemia in a
Danish population. Jour Atherosklerosis 2005;180:155-160.
5. Fodor, G. Am Fam Physician. 2011 May 15;83(10):1207-1208. University of
Ottawa Heart Institute, Ottawa, Ontari, Canada.
http://www.aafp.org/afp/2011/0515/p1207.html diakses tanggal 17 September
2016.
6. Gencer B, Lambert G, Mach F. PCSK9 inhibitors. Swiss medical weekly
2015; 145:w14094.
7. Gu Hm, Zhang Dw. Hypercholesterolemia, low density lipoprotein receptor
and proprotein convertase subtilisin/kexin-type 9. The journal of biomedical
research 2015;29:356-61.
8. Hendromartono, Tjokroprawiro A, Sutjahjo A, Pranoto A, Murtiwi S, Adi S.
Dislipidemia. Dalam : Tjokroprawiro A, Setiawan B, Pranoto A, Nasronudin,
Santoso D, Soegiarto G, editors. Buku Ajar Ilmu Penyakit Dalam. Surabaya:
Airlangga University Press, 2007; 93-106.
9. Hovingh G Kees, Davidson M. H., Kastelein J. J. P., O'connor A. M.
Diagnosis and treatment of familial hypercholestrolemia. European Heart
Journal.
10. Jain P, Katyal V. Dyslipidemia management by PCSK9 inhibition. J
preventive cardiology 2013; 465-9.

23
11. Lambert G, Sjouke B, Choque B. The PCSK9 decade. Thematic review
series:New lipid and lipoprotein targets for the treatment of cardiometabolic
disease. Journal of lipid research 2012;53;2515-24.
12. Latimer J, Batty JA, Neely R Dermot, Kunadian V, PCSK9 inhibitors in the
prevention of cardiovascular disease. Journal Thrombolysis 2016; DOI
10.1007/s11239-016-1364-1
13. http://www.who.int/mediacentre/factsheets/fs317/en/, diakses tanggal 17
September 2016.
14. National Institute for Health and Clinical Excellence. Identification and
Management of Familial Hypercholestrolemia. NICE Clinical Guideline 71.
2008.
15. National Institute for Health and Clinical Excellence. Lipid Modification:
Cardiovascular risk assessment and the modification of blood lipids for the
primary and secondary prevention of cardiovascular disease. NICE Clinical
Guideline 67. 2008.
16. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. 2013. Dalam:
Erwinanto, Santoso A, Putranto J.N.E, Tedjasukmana P, Surayawan R, Rifqi
S, Kasiman S. (Editor). Pedoman Tatalaksana Dislipidemia Edisi Ke-1. Centra
Communications, Indonesia.
17. Rader JD, Cohen J, Hobb HH. Monogenic hypercholesterolemia : new
insightin pathogenesis and treatment. Jour Clin Invest 2003;111:1795-1803.
18. Rees Alan. Familial Hypercholestrolemia: Underdiagnosed and Untrated.
Euroheart Jour 2008;29:283-284.
19. Robbinson JG, Farnier M, Krempf M, et all. Efficacy and Safety of
Alirocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med
2015;372:1489-99
20. S Emily, Aalst-Cohen, CM Angelique, Jansen dkk. Diagnosis Familial
Hypercholestrolemia: The Relevance of Genetic Testing. European Heart Jour
2006;27;2240-2246
21. Shephered J. The role of the exogenous pathway in hypercholesterolemia.
European hearth journal supplements 2010;2-5.
22. Soegondo S, Purnamasari D. Sindroma metabolik. Dalam : Sudoyo AW,
Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editors. Buku Ajar Ilmu
Penyakit Dalam Ed.5. Jakarta: Interna Publishing, 2009; 1865-72.

24
23. Sudano I, Eckardstein A, Matter CM, Lendmesser U. PCSK9 inhibitors: A
new era for lipid-tergeted therapies. A novel therapeutic approach for patienta
with dyslipidemia. Cardivascular medicine 2015;18; 239-45.
24. Stoekenbroek RM,Kastelein JP, Huijgen R. PCSK9 inhibition: the way
forward in the treatment of dyslipidemia. Preventive of cardiovascular disease.
BMC Medicine 2015;13:258-64.
25. The Cholesterol Charity. Diagnosis of Familial Hypercholestrolemia. Heart
UK. 2010.
26. Tim Biomedis Riset Kesehatan Dasar, Badan Penelitian dan Pengembangan
Kesehatan Kementrian Kesehatan Republik Indonesia. Laporan Riset
Kesehatan Dasar (Riskesdas) Bidang Biomedis. 2010:20-5.

25